Multiple Firsts As Pexidartinib Approved In US - With Warning
Executive Summary
Further progress for Daiichi Sankyo's strategic push into oncology as US issues first approval globally for first-in-class rare disease drug Turalio - but with liver toxicity safeguards.
You may also be interested in...
Keeping Track: FDA OKs AMAG's Vyleesi, But Bronchitol And Quizartinib Draw CRLs
The latest drug development news and highlights from our US FDA Performance Tracker.
Defining REMS Success An Unanswered Question For Daiichi's Pexidartinib
US FDA still deliberating on how best to measure success of the liver safety program for Daiichi's TGCT treatment, but REMS will probably assess both process and outcomes.
Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.